Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?

ABSTRACT:

Background

In recent years, non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have been increasingly prescribed to adults with congenital heart disease (CHD) and atrial arrhythmias without good evidence for either safety or efficacy. To address this gap, we initiated an ongoing prospective global registry (NOTE: non-vitamin K antagonist oral anticoagulants for thromboembolic prevention in patients with congenital heart disease). Using the NOTE registry data, the present study aimed to evaluate the occurrence of any adverse events during the initiation phase (first 30 days) of NOACs in adults with CHD and atrial arrhythmias.

Methods and results

For this prospective observational study, 99 adults with CHD and atrial arrhythmias (median age 49 years [IQR 38-61], 53% ma

SUBMITTER: Yang H 

PROVIDER: S-EPMC5591797 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature